Four dopamine agonists, drugs which stimulate dopamine receptors, apomorphine, piribedil, and the ergot alkaloids lergotrile and bromocriptine, have been used to treat patients with Parkinson's disease. Apomorphine is of little clinical value as it must be given by injection, the effects are short lived, and it causes profound vomiting (Cotzias et al., 1970) . Piribedil, although effective in animal models of Parkinsonism, causes slight or no improvement in man, and adverse reactions, vomiting, and sedation are frequent (Vakil et al., 1973) . Lergotrile has a definite antiParkinsonism effect, particularly upon tremor, but some patients rapidly become tolerant (Lieberman et al., 1975) . All these drugs inhibit prolactin secretion, and bromocriptine, 2-Bralpha-ergocryptine, was developed for this purpose (Pozo et al., 1972) . In an attempt to improve the treatment of the considerable number of patients with Parkinson's disease who respond poorly to levodopa, or in whom this drug causes severe side-effects, Calne et al. (1974) , gave bromocriptine to patients with idiopathic (Accepted 18 September 1975.) 
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Parkinson's disease. This caused a 1020% reduction in the disability of patients already receiving levodopa. The side-effects of bromocriptine treatment, emesis and involuntary movements, were similar to those caused by levodopa, although the duration of drug action, eight to 12 hours, was longer than that of levodopa. As well as inhibiting prolactin secretion, bromocriptine has other hormonal effects and causes a variable increase in the plasma concentration of growth hormone in normal subjects, and a reduction in acromegalics (Cammani et al., 1975) . These changes in plasma growth hormone concentration are likely to be due to the effects of bromocriptine on hvpothalamic dopamine receptors.
We have studied the anti-Parkinsonism action of bromocriptine in untreated patients with Parkinson's disease and in others on levodopa therapy. The dosage of bromocriptine that causes clinical improvement or side-effects varies in individual patients, so optimum dosage was first determined separately in each patient, followed by a double-blind controlled trial of placebo and bromocriptine. Plasma growth hormone concentration was also determined to see whether changes in this accompanied clinical improvement due to bromocriptine.
METHODS
PATIENTS Thirty-one patients with idiopathic Parkinson's disease attending King's College Hospital were treated with bromocriptine. Eleven patients had not been treated previously with levodopa, and eight of these had received no previous medication. The disability of most of these patients was slight. In the remaining 20 patients, bromocriptine was added to levodopa treatment. These patients were selected for bromocriptine treatment as they had only a slight or moderate response to levodopa and other anti-Parkinsonism drugs, or were unable to tolerate full therapeutic doses because of side-effects. These patients were mostly moderately or severely disabled.
Eleven patients (eight on levodopa, three on no other treatment) did not persist with bromocriptine treatment because of adverse reaction or absence of obvious short-term clinical improvement. The remaining 20 patients completed a 12 week period taking increasing doses of bromocriptine to establish each individual's maximum tolerated dose up to a limit of 40 mg daily. These 20 patients then took part in a double-blind controlled trial of bromocriptine and placebo treatment. Eleven of these patients were male and nine female, aged 51-72 years (mean 62). Disease duration was from one to 33 years (mean 12.9), and disability was slight in six patients, moderate in nine, and severe in five. Before bromocriptine treatment, the total disability score was from 4-84 (mean 42). Three patients had a unilateral thalamolysis, and two had bilateral.
Bromocriptine was given as the only treatment to five patients and was added to existing medication in 15. Twelve of these patients were on levodopa, and eight were not. Four patients were on a stable dose of levodopa (1.5-7 g daily), and eight were on levodopa combined with a dopa decarboxylase inhibitor, 1-alpha methyl dopa hydrazine (Sinemet), 1.5-6 tablets daily. Levodopa treatment had been taken for one to five years (mean 3.9). Two of these patients had not shown a useful response to levodopa. Eight patients were taking anticholinergic drugs, and eight amantadine 200-300 mg daily. All medication apart from bromocriptine was continued unchanged throughout the trial period. (Marsden et al., 1973 (Fig. 1) . In 12 patients on levodopa, the mean total disability score was reduced by a further 10.0 (21,') on the addition of bromocriptine, and in eight patients not on levodopa, by 9.4 (26%). In the five patients on no other treatment, the mean total disability score was reduced by 9.3 (440 %). The response was similar in both sexes, the reduction in mean total disability score being 9.6 in men and 10.0 in women. The degree of disability before commencement of bromocriptine treatment was Table 2 ). Ten patients showed a reduction in total disability score during bromocriptine compared with placebo, three showed little change, and three showed an increase. In the majority of patients, sub-scores for tremor, akinesia, rigidity, and posture were less during bromocriptine than during placebo treatment, although akinesia scores were higher in three patients, and rigidity scores in four, on active treatment.
FACTORS DETERMINING BROMOCRIPTINE RESPONSE
In the 16 patients who completed the doubleblind trial, no definite clinical factor could be identified which determined response to bromocriptine, although the least disabled patients, and also those not on levodopa, had the greatest reduction in total disability score on bromocriptine compared with placebo. However, there was no significant correlation between age, sex, disease duration, or thalamolysis, and the reduc- Patients who were slightly disabled responded better to bromocriptine than patients with more severe degrees of disability. Thus, the two patients who were initially least disabled (one on levodopa and the other not) both had a 500 % or greater reduction in total disability score on bromocriptine, while the two patients who were most disabled before bromocriptine treatment (one on levodopa and the other not) had little or no reduction in scores in bromocriptine.
Ten patients had a reduction in total disability scores on bromocriptine as compared with placebo, three showed no change, and three an increase. All three of the patients who responded best to bromocriptine were moderately disabled (pre-treatment scores 20, 34, and 40) and the disease duration was one, nine, and 32 years respectively. The three patients who deteriorated on bromocriptine were also moderately disabled (pre-treatment total disability scores 20, 40, and 51). Two of these patients had previously responded well to levodopa. The duration of disease in these three patients was three, seven, and 10 years respectively.
HUMAN GROWTH HORMONE CONCENTRATION The mean fasting plasma HGH concentration in 20 patients with idiopathic Parkinson's disease was 4.8 + 2.3 ,±g/l. After bromocriptine 2.5 mg (11 patients), 5 mg (six patients), and 10 mg (two patients), the mean HGH concentration at 60 minutes was 1.36 + 0.3 ,tg/l, 1. ±+ 0.4, and 0.1 +0.1 respectively; and after 120 minutes was 1.3 + 0.5, 2.6 + 1.3, and 1.5 + 1.5 (mean + I SEM).
During this period no patient had an HGH concentration greater than 7.8 ptg/l. One patient given 1, 5, 10, and 15 mg oral bromocriptine On different days had a peak HGH concentration above 40 pg/l at 120 minutes after the highest dosage, but no response up to 120 minutes with lower dosages. The two patients with the greatest reduction in total disability scores on bromocriptine as com-pared with placebo had no increase in plasma HGH concentration at 120 minutes after 2.5 mg bromocriptine. The three patients with no reduction in total disability scores on bromocriptine compared with placebo showed minor changes in plasma HGH concentration (from 0.5-2.7; 2.7-5.1, and 0.5-1.0 ,g/l) before and 120 minutes after 2.5 mg bromocriptine. The single patient with a considerable increase in HGH concentration after bromocriptine 15 mg responded well to this dosage, with an 80% reduction in total disability score compared with placebo. The correlation between the plasma HGH concentration 120 minutes after 2.5 mg bromocriptine, and the change in disability on bromocriptine in optimum dosage compared with placebo was not statistically significant r=0.06; P>0.1).
SIDE-EFFECTS OF BROMOCRIPTINE TREATMENT
Nine of 31 patients on bromocriptine developed side-effects of sufficient severity to prohibit prolonged treatment. Two patients taking 2.5 and 15 mg had persistent nausea and vomiting for four and 12 weeks, and four patients taking 2.5, 5, 17.5, and 20 mg became hallucinated during the initial eight weeks of treatment. One patient taking 2.5 mg developed stiffness of the neck and headache, and two patients taking 2.5 and 10 mg also on levodopa, had increasing severity of levodopa dyskinesias. None of these patients had a marked therapeutic response to bromocriptine during this period and so treatment was stopped. Two other patients developed no side-effects but did not continue bromocriptine.
In the remaining 20 patients, the side-effects attributed to bromocriptine were similar in nature to those caused separately by levodopa, with the exception of nasal stuffiness, headache, and aching of the neck muscles which occurred in one patient.
Nausea and vomiting was less common in patients on bromocriptine than previously experienced in other patients taking levodopa, 80% of whom were nauseated at some stage of (1974) . In most patients the degree of improvement in motor disability was probably greater than that caused by anticholinergic drugs when given alone, but not as great as that produced by levodopa in conventional dosages. Improvement began within a few days of starting bromocriptine in patients taking no other treatment. Over the three month period of the study about twothirds of patients showed some response but a third did not. Some of these patients who did not respond to bromocriptine had previously responded well to levodopa. There was some evidence to suggest that the therapeutic action of bromocriptine is dose-dependent, although dosage was often limited or treatment had to be stopped because of side-effects. However, greater benefit may be obtained by doses higher than the maximum administered in this trial (40 mg) provided that the patient can tolerate them.
The side-effects of bromocriptine were qualitatively similar to those of levodopa. Hallucinations and mental confusion were common in patients in whom bromocriptine was added to levodopa but may be less common side-effects when bromocriptine is given as a single treatment. Other psychotic episodes were not produced by bromocriptine and this had little or no effect on mood. In contrast with levodopa and apomorphine, nausea and vomiting were seldom caused by bromocriptine. Abnormal involuntary movements similar to those produced by levodopa were also caused by bromocriptine and the severity of levodopa dyskinesias was increased by this treatment. Bromocriptine did not cause symptomatic postural hypotension and no haematological or biochemical alterations were found during the period of this study.
Response variations of minor or major degree are a considerable problem of levodopa treatment. In some patients the clinical effects of a single oral dose of levodopa are obvious up to two to four hours, followed by deterioration until subsequent doses are taken. In others, 8% of our patients, the chronic use of levodopa leads to violent fluctuations in response (yo-yoing), not clearly related in time to separate dosages. In patients on bromocriptine alone the response throughout the day remained stable. However, attempts to treat two patients with response variations by the substitution of bromocriptine for levodopa, have not totally abolished these swings.
Some patients with Parkinson's disease do not respond to levodopa. Levodopa requires conversion to dopamine by dopa decarboxylase in the brain to exert its therapeutic action, and it is possible that in some patients with severe pathology insufficient quantities of this enzyme are present. A theoretical advantage of dopamine agonists such as bromocriptine is that their action is independent of that of dopa decarboxylase. In patients with severe degrees of nigrostriatal damage the receptor response to dopamine agonists may be increased if supersensitivity of denervated receptors occurs. These considerations might suggest that severely disabled patients would show the best response to bromocriptine and that some levodopa failures would benefit (Calne et al., 1974) . However, neither proved to be the case in this trial. The less disabled patients showed the best response to bromocriptine. and patients who had previously not responded to levodopa did not show any useful benefit.
Bromocriptine 2.5 mg given as a single oral dose causes a rise in plasma HGH concentration in most but not all normal subjects aged 28-40 years. The peak increase of 4.0-31 ,g/l (mean 12.5) occurs between 90 and 150 minutes after dosage (Cammani et al., 1975) . In the present study no patient with Parkinson's disease showed an obvious increase in HGH concentration up to 120 minutes after this dosage of bromocriptine and only a single patient had an increase after higher dosage. The increase in plasma HGH concentration after the dopamine agonist apomorphine is less in older than younger subjects, and patients with Parkinson's disease on chronic levodopa treatment may not show the expected rise in HGH concentration after levodopa (Maany et al., 1975; Malarkey et al., 1974) .
However, untreated patients with Parkinson's disease show a normal rise in plasma HGH concentration after levodopa 0.5-1.0 g, and the failure of such patients to respond to bromocriptine 2.5 mg may be because this dosage is too small to cause significant stimulation of hypothalamic dopamine receptors. The single patient in whom bromocriptine 15 mg caused an increase in HGH concentration also had a good therapeutic response, although it is not known whether dopamine receptors at different sites in the nervous system respond in a similar or different manner to dopamine agonist drugs.
The anti-Parkinsonism activity and side-effects of bromocriptine, piribedil, apomorphine, and lergotrile are similar in nature, although quantitatively different. None of these dopamine agonist drugs appears to have as potent a therapeutic effect as levodopa although all have considerable activity in animal models of Parkinsonism (Anden et al., 1967; Corrodi et al., 1971; Corrodi et al., 1973; Calne et al., 1974) . Many of these animal models of Parkinsonismand, in particular, the rotating animal with complete unilateral destruction of one nigrostriatal dopamine system but no other pathology -appear to be of limited value in predicting the value of different drugs in the treatment of human Parkinsonism. In dosages used in man, piribedil may be the least effective and apomorphine the most. Apomorphine almost always causes vomiting; this is uncommon with bromocriptine. Piribedil often results in psychotic episodes; these are less frequent with bromocriptine. Apomorphine sometimes reduces the severity of levodopa dyskinesias (Diuby et al., 1973) , while these are increased by bromocriptine. All these drugs cause a reduction in plasma prolactin concentration, and those studied cause an increase in growth hormone concentration. These different effects may result from the different dosages of each drug used and different degrees of penetration into the brain. Alternatively, there may be different dopamine receptor types within the central nervous system; however, the ideal of a specific nigrostriatal dopamine receptor agonist drug to treat Parkinson's disease has not been achieved. The action of these drugs may be partly dependent on presynaptic effects as well as due to direct receptor stimulation, and their therapeutic effects in Parkinsonism are possibly limited in the presence of presynaptic neuronal degeneration.
